Malamut Richard

SEC source: 0001919246-26-000055 · wk-form4_1775509399.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,422

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F3 · price: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001919246-26-000055 · wk-form4_1775509399.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,702

F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001919246-26-000045 · wk-form4a_1775079878.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,904

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001753926-25-001103 · ownership.xml · derivative · entry 2

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,230

Underlying: Common Stock · 58,230 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

SEC source: 0001753926-25-001103 · ownership.xml · derivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,012

Underlying: Common Stock · 19,108 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

F3 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001919246-26-000045 · wk-form4a_1775079878.xml · nonDerivative · entry 3

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,012

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001753926-24-001949 · ownership.xml · derivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,098

Underlying: Common Stock · 24,533 shares

Expires 2024-11-13

F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

SEC source: 0001753926-24-001578 · ownership.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Jointly held with spouse

Disclosed balance after: 91,565

F1 · price: This price represents the weighted average price of the shares purchased ranging from $0.9206 to $0.9554 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001131 · ownership.xml · derivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,165

Underlying: Common Stock · 64,498 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001919246-26-000045 · wk-form4a_1775079878.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,450

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001062993-22-004326 · form4.xml · nonDerivative · entry 4

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,264

F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

SEC source: 0001062993-22-004326 · form4.xml · nonDerivative · entry 3

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,102

F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

SEC source: 0001062993-22-004326 · form4.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,564

F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 6,256 performance share units granted in the issuer's two prior fiscal years.

SEC source: 0001062993-22-004326 · form4.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,308

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

SEC source: 0001192482-21-000322 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,558

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

SEC source: 0001192482-21-000146 · edgar.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,677

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

SEC source: 0001192482-21-000146 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,219

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

SEC source: 0001192482-21-000088 · edgar.xml · derivative · entry 3

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,600

Underlying: Common Stock · 105,600 shares

Expires 2031-01-19

F3 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.

SEC source: 0001192482-21-000088 · edgar.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,977

F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 2,187 performance share units granted in a prior year.

SEC source: 0001192482-21-000088 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,790

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

SEC source: 0001192482-21-000092 · edgar.xml · nonDerivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,977

F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 2,187 performance share units granted in a prior year.

SEC source: 0001192482-21-000092 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,790

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

SEC source: 0001192482-20-000272 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,830

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

SEC source: 0001192482-20-000139 · edgar.xml · derivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-02-05

F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.

SEC source: 0001192482-20-000139 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,750

F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2021, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

SEC source: 0001192482-19-000182 · edgar.xml · derivative · entry 2

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2029-04-01

F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on April 1, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three year period, subject to the reporting person's continued service with the issuer.

SEC source: 0001192482-19-000182 · edgar.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,500

F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on April 1, 2020, and the balance of the restricted stock units vest in equal annual installments (in each case, rounded up to the nearest whole share of common stock) over the following three year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.